Modality
Small Molecule
MOA
WRNi
Target
PARP
Pathway
Cell Cycle
FabryRCCCTCL
Development Pipeline
Preclinical
~Dec 2012
→ ~Mar 2014
Phase 1
~Jun 2014
→ ~Sep 2015
Phase 2
~Dec 2015
→ ~Mar 2017
Phase 3
Jun 2017
→ Apr 2028
Phase 3Current
NCT08236716
1,975 pts·CTCL
2017-06→TBD·Active
NCT08533117
2,294 pts·Fabry
2021-05→2028-04·Active
4,269 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-042.0y awayPh3 Readout· Fabry
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P3
Active
P3
Active
Catalysts
Ph3 Readout
2028-04-04 · 2.0y away
Fabry
Active|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |